Dr. Xu is Associate Director of the Tissue Typing Laboratory, which provides 24 hr/7 day service to the solid organ and bone marrow transplant programs.
Clinical Expertise
Dr. Xu has more than 10-year experience in clinical histocompatibility and immunogenetics, and has been the director of ASHI-certified HLA labs in Canada. He was known for his expertise in quality improvement and timely consultation to transplant teams. Currently, Dr. Xu is the Associate Director of the Histocompatibility (Tissue Typing) Lab at UPMC. The lab provides comprehensive histocompatibility services to multiple solid organs and hematopoietic stem cell transplant programs in the UPMC system, VA hospital, and Western Virginia. Dr. Xu is an expert in test interpretation, immunological risk assessment for organ transplantation, and hematopoietic stem cell transplantation. Specifically, Dr. Xu provides consultation to clinicians regarding patient/donor selection and therapeutic regimens before transplantation, diagnosing, and treatment of rejection after transplantation.
- Autoantibodies in organ transplantation, especially in liver transplantation. Previously, we had reported that pre-formed Angiotensin II Type I Receptor agonistic autoantibodies (AT1R-AA) are associated with poor allograft survival in liver re-transplantation (Xu, et al, AJT, 2019). Currently, we are studying other autoantibodies in liver, lung, and heart transplantations to establish evidence for using autoantibodies testing to improve outcomes of organ transplantation.
- Monitoring Anti-HLA antibody in pre-transplantation desensitization and treatment of antibody-mediated rejections. Novel approaches to monitoring allospecific humoral and cellular responses for better clinical decision making.
- HLA immunogenicity and its applications in risk stratification of organ transplantation.
Dr. Xu's full publications: Qingyong Xu - Google Scholar.
- McCaughan J, Xu Q, Tinckam K. Detecting DSA: the importance of sorting the wheat from the chaff. HepatoBiliary Surgery and Nutrition, 2019 Jun 10; 8 (1): 37-52. (Communication author)
- Xu Q, House AA, Leckie S, Gunaratnam L, Luke PP, Jevnikar AM. Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch. Hum Immunol. 2019; 80:487–492. (Communication author)
- Xu Q, Shrum B, Leckie S, Skaro A, McAlister VC. The impact of donor-specific alloantibodies on long-term outcomes of liver re-transplantation. HepatoBiliary Surgery and Nutrition, 2019 Jun 9; 8 (3): 246-252
- Xu Q, McAlister VC, Leckie S, House AA, Skaro A, Marotta P. Angiotensin II Type I Receptor Agonistic Autoantibodies are Associated with Poor Allograft Survival in Liver Re-transplantation. American Journal Transplantation, 2019 Aug 16; 20:282–288. doi: 10.1111/ajt.15571. (Communication author)
- Wood-Trageser, M.A., Xu Q, Zeevi A, Randhawa P, Lesniak D, Demetris, AJ. Precision transplant pathology, Current Opinion in Organ Transplantation: June 08, 2020; 25(4):412-419.
- Hosseini-Moghaddam SM, Xu Q, Jevnikar AM, House AA, Luke P, Campigotto A, Kum JJY, Singh G, Alharbi H, Speechley MR. The effect of human leukocyte antigen A1 and B35-Cw4 on sustained BK polyomavirus DNAemia after renal transplantation. Clin Transplant. 2020 Oct 14:e14110. doi: 10.1111/ctr.14110.
- Xu Q, Mangiola M., Zeevi A. Choosing the right patient for lung transplantation: assessment of histocompatibility and sensitization status. Contemporary Lung Transplantation. 2021
- Xu Q, McAlister VC, House AA, Molinari M, Leckie S, Zeevi A. Autoantibodies to LG3 are Associated with Poor Long-term Survival after Liver Re-transplantation. Clin Transplant. 2021. doi: 10.1111/ctr.14318. (Communication author)
- Sriwattanakomen R, Xu Q, Demehin M, Shullo MA, Mangiola M, Hickey GW, Sciortino CM, Horn ET, Keebler ME, Zeevi A. Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates. J Heart Lung Transplant. 2021 Mar 5:doi: 10.1016/j.healun.2021.03.001. (Co-first author)
- Xu Q, Sood P, Helmick D, Lomago JS, Tevar AD, Zeevi A. Positive flow cytometry crossmatch with discrepant antibody testing results following COVID-19 vaccination. Am J Transplant. 2021;00:1–5. https://doi.org/10.1111/ajt.16753. (Communication author)